{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:42:48Z","timestamp":1788090168640,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Pembrolizumab is standard adjuvant therapy for high-risk clear cell renal cell carcinoma, but serositis is an uncommon immune-related adverse event that may mimic recurrence or infection. We report a 55-year-old man who achieved no evidence of disease after nephrectomy and metastasectomy and developed anasarca, large bilateral pleural effusions, mild ascites, peripheral eosinophilia, and a small pericardial effusion after six cycles of adjuvant pembrolizumab. Pleural fluid was exudative and contained 20% eosinophils. Cytology showed inflammatory cells without evidence of malignancy; bacterial, mycobacterial, and fungal studies were negative; and mildly elevated adenosine deaminase did not support tuberculosis. Cardiac function and natriuretic peptides were preserved. Pembrolizumab was discontinued, thoracentesis and corticosteroids were administered, and symptoms, eosinophilia, renal function, and albumin improved rapidly. Follow-up through March 2026 showed no oncologic progression, although some residual pleural and abdominal fluid persisted alongside imaging findings suggestive of portal-hypertension physiology, which may have contributed to residual fluid but did not explain the eosinophilic pleural syndrome. In a targeted literature review, effusion eosinophil data were infrequently reported. This case highlights a likely underrecognized eosinophilic pleural-fluid phenotype within pembrolizumab-associated polyserositis and supports routine differential cell counts in drained serosal fluid when immune-related serositis is suspected.<\/jats:p>","DOI":"10.3390\/curroncol33060314","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T11:03:27Z","timestamp":1779879807000},"page":"314","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab-Associated Polyserositis with Eosinophilic Pleural Effusion During Adjuvant Therapy for Clear Cell Renal Cell Carcinoma: A Case Report and Targeted Review"],"prefix":"10.3390","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-6953-1490","authenticated-orcid":false,"given":"Mikel","family":"Portu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7526-4973","authenticated-orcid":false,"given":"Judit","family":"Sanz-Beltran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Alejandra","family":"Duarte Borges","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julieta","family":"Navarro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Arias","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Fern\u00e1ndez-Rebollo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Reyes","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Flores","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6060-1110","authenticated-orcid":false,"given":"Georgia","family":"Anguera","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_3","unstructured":"European Association of Urology (2026). EAU Guidelines on Renal Cell Carcinoma, Limited Update March 2026, European Association of Urology. Available online: https:\/\/uroweb.org\/guidelines\/renal-cell-carcinoma."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e002435","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) Clinical Practice Guideline on Immune Checkpoint Inhibitor-Related Adverse Events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","article-title":"Pericardial disease in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gong","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40959-024-00234-0","article-title":"Immune checkpoint inhibitors and pericardial disease: A systematic review","volume":"10","author":"Mudra","year":"2024","journal-title":"Cardio-Oncology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","article-title":"Immune checkpoint inhibitors-associated pericardial disease: A systematic review of case reports","volume":"70","author":"Inno","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"4964","DOI":"10.1093\/eurheartj\/ehab618","article-title":"Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: A safety meta-analysis","volume":"42","author":"Dolladille","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1007\/s00262-022-03211-7","article-title":"Checkpoint-inhibitor induced Polyserositis with Edema","volume":"71","author":"Zierold","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.2169\/internalmedicine.7219-21","article-title":"Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab","volume":"60","author":"Sawada","year":"2021","journal-title":"Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ejca.2022.11.001","article-title":"Immune-related generalised oedema\u2014A new category of adverse events with immune checkpoint inhibitors","volume":"179","author":"Velev","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1722022","DOI":"10.1080\/2162402X.2020.1722022","article-title":"Moderate-to-severe eosinophilia induced by treatment with immune checkpoint inhibitors: 37 cases from a national reference center for hypereosinophilic syndromes and the French pharmacovigilance database","volume":"9","author":"Scanvion","year":"2020","journal-title":"OncoImmunology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1002\/ijc.35398","article-title":"Eosinophil-induced adverse events induced by treatment with programmed cell death 1\/ligand 1 inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"157","author":"Lyu","year":"2025","journal-title":"Int. J. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejca.2017.05.017","article-title":"Immune-related eosinophilia induced by anti-programmed death 1 or death-ligand 1 antibodies","volume":"81","author":"Jeanville","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/0002-9343(84)90542-4","article-title":"Diagnostic utility of pleural fluid eosinophilia","volume":"77","author":"Adelman","year":"1984","journal-title":"Am. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00063198-200307000-00002","article-title":"Eosinophilic Pleural Effusions","volume":"9","author":"Kalomenidis","year":"2003","journal-title":"Curr. Opin. Pulm. Med."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aggarwal, A.N., Agarwal, R., Sehgal, I.S., and Dhooria, S. (2019). Adenosine deaminase for diagnosis of tuberculous pleural effusion: A systematic review and meta-analysis. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0213728"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, M., Zeng, Y., Li, Y., Jia, D., Chen, S., and Wang, J. (2021). Incidence, aetiology and clinical features of eosinophilic pleural effusion: A retrospective study. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01767-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7326\/0003-4819-77-4-507","article-title":"Pleural Effusions: The Diagnostic Separation of Transudates and Exudates","volume":"77","author":"Light","year":"1972","journal-title":"Ann. Intern. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000447053","article-title":"Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion","volume":"136","author":"Kushnir","year":"2016","journal-title":"Cardiology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ijcard.2016.08.023","article-title":"Pericardial effusion with tamponade physiology induced by nivolumab","volume":"222","author":"Nesfeder","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/08998280.2022.2132367","article-title":"Rechallenging nivolumab following immune checkpoint inhibitor\u2013induced pericarditis","volume":"36","author":"Ali","year":"2022","journal-title":"Bayl. Univ. Med. Cent. Proc."},{"key":"ref_26","first-page":"004237","article-title":"A case of polyserositis, chylous ascites and hepatitis induced by immune checkpoint-inhibitors","volume":"11","author":"Castelli","year":"2024","journal-title":"Eur. J. Case Rep. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s40425-019-0760-4","article-title":"Pericardial effusion under nivolumab: Case-reports and review of the literature","volume":"7","author":"Saade","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/CJI.0000000000000217","article-title":"Immune-Mediated Pericarditis with Pericardial Tamponade during Nivolumab Therapy","volume":"41","author":"Gomes","year":"2018","journal-title":"J. Immunother."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s40425-016-0152-y","article-title":"Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy","volume":"4","author":"Heinzerling","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e933396-1\u2013e933396-4","DOI":"10.12659\/AJCR.933396","article-title":"Chronic Pleuritis and Recurrent Pleural Effusion After Atezolizumab for Small Cell Lung Cancer","volume":"22","author":"Lin","year":"2021","journal-title":"Am. J. Case Rep."},{"key":"ref_31","first-page":"100156","article-title":"Progressive Pleural Effusion as an Immune-Related Adverse Event in NSCLC: A Case Report","volume":"2","author":"Shen","year":"2021","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40164-018-0104-y","article-title":"Conservative management of nivolumab-induced pericardial effusion: A case report and review of literature","volume":"7","author":"Shaheen","year":"2018","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1093\/annonc\/mdx214","article-title":"Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment","volume":"28","author":"Yanagihara","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1177\/10781552231179369","article-title":"An unusual case of checkpoint-inhibitor-induced pleuropericarditis","volume":"29","author":"Suarez","year":"2023","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"ytaf400","DOI":"10.1093\/ehjcr\/ytaf400","article-title":"A case report of fulminant eosinophilic myo-pericarditis related to checkpoint inhibitors complicated by acute heart failure and cardiac tamponade","volume":"9","author":"Betz","year":"2025","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e009658","DOI":"10.1136\/jitc-2024-009658","article-title":"Targeted inhibition of the IL5 axis for immune checkpoint inhibitors eosinophilic-induced adverse events","volume":"12","author":"Rubin","year":"2024","journal-title":"J. Immunother. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.jacc.2025.05.023","article-title":"2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee","volume":"86","author":"Wang","year":"2025","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s40425-016-0185-2","article-title":"Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy\u2013A report of two cases","volume":"4","author":"Kolla","year":"2016","journal-title":"J. Immunother. Cancer"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40425-018-0334-x","article-title":"Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer","volume":"6","author":"Sweis","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"ytad112","DOI":"10.1093\/ehjcr\/ytad112","article-title":"Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: A case report","volume":"7","author":"Verhaert","year":"2023","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"ytab002","DOI":"10.1093\/ehjcr\/ytab002","article-title":"Refractory constrictive pericarditis caused by an immune checkpoint inhibitor properly managed with infliximab: A case report","volume":"5","author":"Moriyama","year":"2021","journal-title":"Eur. Heart J. Case Rep."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Chye, A.M., Nordman, I.I.C., and Sverdlov, A.L. (2022). Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series. Front. Cardiovasc. Med., 9.","DOI":"10.3389\/fcvm.2022.964324"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"bcr2013201554","DOI":"10.1136\/bcr-2013-201554","article-title":"The CARE Guidelines: Consensus-Based Clinical Case Reporting Guideline Development","volume":"2013","author":"Gagnier","year":"2013","journal-title":"BMJ Case Rep."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/314\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:10:39Z","timestamp":1779883839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/33\/6\/314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":44,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["curroncol33060314"],"URL":"https:\/\/doi.org\/10.3390\/curroncol33060314","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]}}}